Novo Nordisk A/S (NVO)
| Market Cap | 249.87B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.93 |
| PE Ratio | 14.29 |
| Forward PE | 14.67 |
| Dividend | $1.23 (2.18%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 9,116,359 |
| Open | 56.05 |
| Previous Close | 56.11 |
| Day's Range | 55.71 - 56.53 |
| 52-Week Range | 45.05 - 139.74 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 98.00 (+73.57%) |
| Earnings Date | Aug 6, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $98.0, which is an increase of 73.57% from the latest price.
News
Denmark cuts growth forecast as Novo slowdown sparks reliance debate
Denmark's government has lowered its 2025 economic growth forecast to 1.4% from a previous projection of 3%, citing weaker prospects for pharmaceutical giant Novo Nordisk and new tariffs on Danish exp...
Ozempic Maker Novo Nordisk Is a Problem as Denmark's Economy Hits a Wall
The economy ministry blamed the slowdown on U.S. tariffs, but faltering demand for Ozempic and Wegovy could be another factor.
Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown
Denmark on Friday slashed its annual growth forecast to 1.4% from 3%. In this article NOVO.B-DK
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options
Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk's Wegovy in MASH, According to Spherix Global Insights
US Gastroenterologists and hepatologists highlight strong interest in Wegovy for addressing the metabolic roots of MASH. US Gastroenterologists and hepatologists highlight strong interest in Wegovy fo...
Novo Nordisk seeks new obesity, diabetes drugs with Replicate BioScience partnership
Replicate Bioscience will partner with Novo Nordisk to develop treatments using self-replicating RNA technology for obesity, type 2 diabetes and other cardiometabolic diseases, the privately held biot...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired se...
Form Health Selected for Novo Nordisk's NovoCare® Platform to Expand Access to Science-Based Obesity Care Across the United States
BOSTON--(BUSINESS WIRE)--Today, Form Health, the leading provider of science-based obesity and cardiometabolic care in the United States, announced its selection as a healthcare provider option on Nov...
Novo Holdings Announces Sale of KabaFusion
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Novo Holdings, a leading healthcare investment firm, announced that it has signed a definitive agreement to successfully exit its investment in KabaFusion (th...
Novo Nordisk: Undervalued Pharma Heavyweight With Upside Potential
Novo Nordisk is deeply undervalued, trading at a forward P/E of 14, despite 20%+ top and bottom-line growth and dominant weight-loss market share. The anti-obesity market is set to grow nearly 10x by ...
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Some analysts say Eli Lilly's daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors. In the trial...
Eli Lilly Vs. Novo Nordisk: One Stock Is Massively Undervalued, The Other Overvalued
Novo Nordisk and Eli Lilly both declined significantly in the last months. This was mainly caused by efficacy uncertainty, further competition and political headwinds. Despite the sell-offs, I current...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Novo Nordisk: This Options Strategy Was Profitable Even With The Stock Down
Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international markets and new launches support the outlook. My updated fair value estima...
Novo Nordisk Freezes Hiring in Noncritical Areas
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost controls amid challenges in the obesity-drug market.
Riding high on Wegovy, Novo doubled its workforce. Now layoffs loom
As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...
Navigating The Novo Nordisk Case With The Inversion Mental Model
In this article I'll use Charlie Munger's inversion model to analyze Novo Nordisk's potential failure points. We'll go over the recent market share loss, supply chain issues, their R&D pipeline, and t...
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
Bagsværd, Denmark, 20 August 2025 – Novo Nordisk today announced new data showing the cardiovascular protective benefits of Wegovy ® and Ozempic ® will be presented at the European Society of Cardiolo...
Novo Nordisk: Cleared For A Climb
Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals, a healthy balance sheet, and solid management. Recent stock weakness stems from sector-wide regulatory f...
Drugmaker Novo Nordisk enacts worldwide hiring freeze for non-critical job roles
Wegovy-maker Novo Nordisk has implemented a global hiring freeze, which covers job roles that are not critical for its business, the company said on Wednesday.
Ozempic lowers price for diabetes patients who pay cash
Patients can now get a month's supply for $499 if they don't go through insurance. Transcript: CAROLINE WOODS: Diabetes drug prices are getting a shake-up.
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data
Eli Lilly and Co. LLY and Novo Nordisk A/S NVO are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from ...
UnitedHealth Vs. Novo Nordisk: Which Healthcare Giant Fits Your Portfolio?
Two healthcare giants, UnitedHealth Group Inc UNH and Novo Nordisk A/S NVO, are duking it out in very different ways for investors' attention. Both stocks have faced heavy losses this year—UNH down 38...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated perso...
BioMed X and Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
Heidelberg, Germany--(Newsfile Corp. - August 19, 2025) - BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with No...